Alirocumab Effective in Homozygous FH Alirocumab Effective in Homozygous FH

PCSK9 inhibitor alirocumab lowered LDL cholesterol by 35% over placebo in ODYSSEY HoFH, the largest ever randomized lipid-lowering trial in homozygous familial hypercholesterolemia.Medscape Medical News
Source: Medscape FamilyMedicine Headlines - Category: Primary Care Tags: Cardiology News Source Type: news